Last A$4.02 AUD
Change Today -0.04 / -0.99%
Volume 495.7K
MSB On Other Exchanges
As of 12:10 AM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

mesoblast ltd (MSB) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/14 - A$6.08
52 Week Low
10/16/14 - A$3.64
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MESOBLAST LTD (MSB)

Related News

No related news articles were found.

mesoblast ltd (MSB) Details

Mesoblast Limited, a biotechnology company, is engaged in the research and development of its propriety stem cell technologies for use in the treatment of multiple major disease states and other medical conditions. The company’s cell-based core technologies include immunoselected mesenchymal precursor cells (MPCs), culture-expanded mesenchymal stem cells (MSCs), dental pulp stem cells, and expanded hematopoietic stem cells. Its lead products include MSC-100-IV, which is used for the treatment of steroid refractory acute graft versus host disease and biologic refractory crohn’s disease; MPC-06-ID that is used for the treatment of chronic low back pain; and MPC-150-IM, which is used for congestive heart failure treatment. The company also offers supporting products, such as MPC-300-IV, an intravenously administered MPCs that are used for the treatment of type 2 diabetes, liver/kidney complications, and rheumatoid arthritis; MPC-25-IC, which is used for the treatment of acute myocardial infarction; MPC-25-Osteo for use in surgical bone repair; MPC-CBE that is used in bone marrow transplantations; and MPC-MICRO-IO for use in age-related macular degeneration treatment. In addition, it provides various products for the treatment of ophthalmology diseases, neurological diseases, lung diseases, etc. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf (allogeneic) adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its immunoselected MPCs that are used for cardiac and vascular diseases. It has operations in Australia, the United States, and Singapore. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

115 Employees
Last Reported Date: 08/25/14
Founded in 2004

mesoblast ltd (MSB) Top Compensated Officers

Founder, Chairman of Scientific Advisory Boar...
Total Annual Compensation: A$1.8M
Compensation as of Fiscal Year 2014.

mesoblast ltd (MSB) Key Developments

Mesoblast Reports Positive 24 Month Results in Phase 2 Trial for Chronic Low Back Pain and Initiation of Phase 3 Program at JP Morgan Healthcare Conference

Mesoblast Limited presented positive 24-month results from its Phase 2 program for chronic low back pain at the JP Morgan 33rd Annual Healthcare Conference being held in San Francisco. Additionally, Mesoblast announced that its Phase 3 program for this indication has been initiated. Mesoblast presented anticipated timelines for this Phase 3 program and noted that enrollment completion is expected in mid-2016, an interim analysis is expected in mid-2016 and top-line data are expected in mid-2017. In the randomized, placebo-controlled Phase 2 trial of 100 patients with chronic low back pain due to degenerative disc disease, a single injection of Mesoblast's allogeneic investigational mesenchymal precursor cell (MPC) product, MPC-06-ID, was well tolerated and was shown to result in substantial improvement in pain and function for at least 24 months. Highlights of the clinical results were: A single injection of 6 million MPCs induced substantial and sustained pain relief over 24 months. At 12 and 24 months, 46% and 48% of MPC-06-ID-treated patients achieved minimal or no residual pain (VAS less than or equal to 20) compared with 13% and 13% of saline treated patients, p equals 0.042 and 0.093, respectively. In patients who received a single injection of 6 or 18 million MPCs, 44% and 42%, respectively, achieved the target composite endpoint of treatment success at both 6 and 12 months (50% reduction in pain, 15 point improvement in function and no further treatment intervention), compared with 13% of saline controls (p equals 0.006 and p equals 020). In patients who received 6 million MPCs and achieved the target composite endpoint of treatment success at both 6 and 12 months, 86% (11 of 13) maintained treatment success at 24 months (32% vs 11% saline controls, p equals 0.001).

Mesoblast Limited Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 07:30 AM

Mesoblast Limited Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 07:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Silviu Itescu, Founder, Chairman of Scientific Advisory Board, Chief Executive Officer, Managing Director, Executive Director and Member of Science & Technology Committee.

Mesoblast Limited, Annual General Meeting, Nov 25, 2014

Mesoblast Limited, Annual General Meeting, Nov 25, 2014., at 15:30 E. Australia Standard Time. Location: Deloitte Level 11. Agenda: To consider receipt and consideration of financial statements and reports; to consider election and re-election of Directors; to consider election of William M. Burns as a Director; to consider re-election of Donal O'Dwyer as a Director; to consider re-election of Ben-Zion Weiner as a Director; to consider adoption of the remuneration report; and to consider approval of proposed issue of options to Non-Executive Directors.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MSB:AU A$4.02 AUD -0.04

MSB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $4.13 USD +0.25
NeoStem Inc $3.59 USD +0.01
Ocata Therapeutics Inc $6.06 USD -0.04
Osiris Therapeutics Inc $16.90 USD +0.01
Pluristem Therapeutics Inc $2.71 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation MSB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.3x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MESOBLAST LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at